The subsequent analysis of the ADAURA study showed adjuvant osimertinib as an effective treatment for patients with stage IB–IIIA EGFR mutation NSCLC after resection, with or without prior adjuvant chemotherapy [28]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.